THE pending departure of Allan Tillack from his current role as Sandoz general manager in Australia will also see him step down as chair of the Generic and Biosimilar Medicines Association.
Tillack will move to a new regional leadership role within Novartis in the coming months, while at GBMA he will be replaced as chair by Mylan general manager Sylvain Vigneault.
GBMA also recently appointed Marnie Peterson as its new chief executive officer (PD 28 Feb).
The above article was sent to subscribers in Pharmacy Daily's issue from 17 Apr 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 17 Apr 18
